Biotech Values

[biomaven0]

>>I can't think of one company which has recently gotten approval that isn't dramatically lower then the announcement day

ACOR is about 20% higher than it was on its approval date in January this year.

I don't disagree with you on the "manipulation" theories though.

Some months ago I said on this forum that I though the most likely outcome was MNTA approval and a Teva "no decision." Looks like that is where we are. My current guess is that Teva will have to resubmit, and so a competitor is a year or two off. Meantime MNTA should make a fair amount of money, although I believe the Teva overhang will continue to prevent MNTA receiving a decent PE multiple.

My view is nevertheless that MNTA stock will outperform over the next year though.

Peter